Lv0
0 积分 2023-06-15 加入
A pharmacovigilance study on drug-induced liver injury associated with antibody-drug conjugates (ADCs) based on the food and drug administration adverse event reporting system
14小时前
已完结
D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study Results
3个月前
已完结
Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
3个月前
已完结
Small cell carcinoma of the bladder: the characteristics of molecular alterations, treatment, and follow-up
4个月前
已完结
Levels of pretreatment serum lipids predict responses to PD-1 inhibitor treatment in advanced intrahepatic cholangiocarcinoma
6个月前
已完结
First-line PD-1 inhibitors combination therapy for patients with advanced cholangiocarcinoma: A retrospective real-world study
6个月前
已完结
An active trend of immunotherapy combination regimen as second-line therapy for advanced biliary tract cancer: A multicenter retrospective study
7个月前
已完结
Low-grade cutaneous immune-related adverse events leading to immunotherapy discontinuation
1年前
已完结
Early Liver Specialist Consultation is Associated With Faster Biochemical Resolution of Severe Immune Checkpoint Inhibitor–Induced Hepatitis
1年前
已完结
Retreatment with Checkpoint inhibitors after a severe immune-related hepatitis: Results from a prospective multicenter study
1年前
已完结
皖公网安备34019202002308
